<rss version="2.0" 
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
>

<channel>
	<title>News on BioVex from BioPortfolio.com</title>
	<link>http://www.BioPortfolio.com</link>
	<description>Consolidated BioVex news from BioPortfolio.com</description>
	<pubDate>Tue, 09 Feb 2010 23:22:08 GMT</pubDate>
	<language>en</language>
<atom:link href="http://www.bioportfolio.co.uk/cgi-bin/rssnews.pl?q=BioVex" rel="self" type="application/rss+xml" />

	
<item><title>BioVex Announces Broadened Inclusion Criteria In Phase 3 Melanoma Study</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3876982&amp;HITNO=0&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3876982&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2451754799%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3876982&amp;HITNO=0&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3876982&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2451754799%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Medical News Today:</description></item>
<item><title>BioVex Announces Broadened Inclusion Criteria in Phase 3 Melanoma Study</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869080&amp;HITNO=1&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869080&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448096444%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869080&amp;HITNO=1&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869080&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448096444%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharmacy Choice:</description></item>
<item><title>BioVex Announces Broadened Inclusion Criteria in Phase 3 Melanoma Study</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3868919&amp;HITNO=2&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3868919&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2447966231%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3868919&amp;HITNO=2&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3868919&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2447966231%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Therapeutics Daily:</description></item>
<item><title>BioVex names new vice president</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869101&amp;HITNO=3&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869101&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448114584%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869101&amp;HITNO=3&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869101&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448114584%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Individual.com:</description></item>
<item><title>BioVex names new vice president</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869950&amp;HITNO=4&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869950&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448632326%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869950&amp;HITNO=4&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869950&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448632326%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Therapeutics Daily:</description></item>
<item><title>BioVex's Phase 3 melanoma study amended to include first line patients</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869616&amp;HITNO=5&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869616&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448434435%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3869616&amp;HITNO=5&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3869616&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2448434435%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>News-Medical.Net:</description></item>
<item><title>BioVex Announces Broadened Inclusion Criteria in Phase 3 Melanoma Study</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3865222&amp;HITNO=6&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3865222&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446246381%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3865222&amp;HITNO=6&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3865222&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446246381%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Freshnews.com:</description></item>
<item><title>BioVex Announces Broadened Inclusion Criteria in Phase 3 Melanoma Study</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3866408&amp;HITNO=7&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3866408&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446678594%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3866408&amp;HITNO=7&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3866408&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446678594%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharma Live:</description></item>
<item><title>BioVex Announces Broadened Inclusion Criteria in Phase 3 Melanoma Study</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3865023&amp;HITNO=8&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3865023&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446191044%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3865023&amp;HITNO=8&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3865023&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446191044%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Genetic Engineering News:</description></item>
<item><title>BioVex Appoints Tim Hanke as VP Commercial Operations</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3862950&amp;HITNO=9&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3862950&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2445271068%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3862950&amp;HITNO=9&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3862950&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2445271068%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharma Live:</description></item>
<item><title>Biogen Idec's Mullen to step down</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3865355&amp;HITNO=10&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3865355&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446296972%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3865355&amp;HITNO=10&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3865355&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2446296972%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>FierceBiotech:</description></item>
<item><title>BioVex Names Tim Hanke as VP of Commercial Operations</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3862681&amp;HITNO=11&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3862681&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2445125718%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3862681&amp;HITNO=11&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3862681&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2445125718%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Individual.com:</description></item>
<item><title>BioVex Appoints Tim Hanke as VP Commercial Operations</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3853666&amp;HITNO=12&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3853666&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2441156184%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3853666&amp;HITNO=12&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3853666&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2441156184%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>SmartBrief:</description></item>
<item><title>BioVex Appoints Tim Hanke as VP Commercial Operations</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3853067&amp;HITNO=13&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3853067&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2440882273%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3853067&amp;HITNO=13&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3853067&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2440882273%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Genetic Engineering News:</description></item>
<item><title>BioVex Appoints Tim Hanke as VP Commercial Operations</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3854735&amp;HITNO=14&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3854735&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2441620299%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3854735&amp;HITNO=14&amp;MSIZE=15&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=BioVex&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3854735&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2441620299%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>BioSpace:</description></item>
</channel></rss>